Abstract:Improvements in neonatal intensive care have resulted in more extremely low birthweight babies surviving who are at risk of developing chronic lung disease. The preterm lung is vulnerable as it is both structurally immature and deficient in surfactant and antioxidant defences. Mechanical ventilation and high inspired oxygen concentrations are often necessary for preterm babies to survive but they can cause pulmonary inflammation which leads to lung damage. Abnormal healing in the presence of ongoing inflammation leads to airways remodelling which can result in protracted respiratory problems in these babies. A commonly used definition for chronic lung disease is the requirement for supplemental oxygen beyond 36 weeks’ postconception.Many drugs that are commonly used for chronic lung disease have not been subjected to proper randomised controlled trials but are widely used on the basis of small studies showing short term benefits. They can be broadly divided into 2 groups. First, there are preventative drugs that are administered early to reduce oxygen toxicity and pulmonary inflammation. Secondly, there are those administered in established chronic lung disease, designed to reduce respiratory morbidity. Pulmonary inflammation in the neonate is reduced by systemic corticosteroids. Corticosteroid therapy within the first 2 weeks of life enables earlier extubation of preterm babies with subsequent reduced chronic lung disease and improved neonatal survival when given between 7 and 14 days. However, there is an increased risk of gastrointestinal haemorrhage, metabolic derangement, ventricular hypertrophy and potential effects on long term growth and brain development. Diuretics and inhaled bronchodilators improve pulmonary compliance and reduce oxygen requirements in established chronic lung disease but probably have little effect in reducing the incidence. In babies with established chronic lung disease, home oxygen therapy enables earlier discharge and prophylaxis against respiratory syncytial virus can reduce morbidity from bronchiolitis. All of the above therapies have adverse effects that need to be considered before initiating treatment.Recently, new drugs have become available which may be beneficial. These include inhaled nitric oxide for reduction of ventilation-perfusion mismatching, recombinant human superoxide dismutase for protection against oxidative stress and alpha-1 proteinase inhibitor which may reduce airways remodelling. At present these therapies are undergoing clinical trials. Exogenous surfactant is beneficial in respiratory distress syndrome and may reduce the risk of chronic lung disease but there have been no randomised controlled trials of its use in established chronic lung disease. Drugs which have been tried unsuccessfully include erythromycin, ambroxol and mast cell stabilisers.

Respiratory strategy at birth initiates distinct lung injury phenotypes in the preterm lamb lung

MicroRNA-mRNA interactions in a murine model of hyperoxia-induced bronchopulmonary dysplasia

[Lung protective strategies of ventilation in respiratory distress syndrome of neonates].

LSC Abstract – Early biomarkers indicating the development of neonatal chronic lung disease defined by clinical and imaging parameters

Lung protective ventilation does not impact left ventricular function in a preterm lamb model

Impact of neonatal noninvasive resuscitation strategies on lung mechanics, tracheal pressure, and tidal volume in preterm lambs

Acute lung injury in preterm fetuses and neonates: mechanisms and molecular pathways

Nasal ventilation alters mesenchymal cell turnover and improves alveolarization in preterm lambs

Effects of Positive End-Expiratory Pressure, Inhaled Nitric Oxide and Surfactant on Expression of Proinflammatory Cytokines and Growth Factors in Preterm Piglet Lungs

Proteomics reveals region-specific hemostatic alterations in response to mechanical ventilation in a preterm lamb model of lung injury

Biomarkers in Lung Diseases : from Pathogenesis to Prediction to New Therapies Epithelial disruption of Gab 1 perturbs surfactant homeostasis and predisposes mice to lung injuries

Alveolar formation is dysregulated by restricted nutrition but not excess sedation in preterm lambs managed by noninvasive support

Antileukotrienes for the prevention and treatment of chronic lung disease in very preterm newborns: a systematic review

A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease

Neonatal pulmonology: optimizing transition and lung function in preterm infants

Early Changes and Indicators Characterizing Lung Aging in Neonatal Chronic Lung Disease

In utero ventilation induces lung parenchymal and vascular alterations in extremely preterm fetal sheep

Non-invasive versus invasive respiratory support in preterm infants

Early metabolic markers as predictors of respiratory complications in preterm infants with bronchopulmonary dysplasia

Intratracheal Keratinocyte Growth Factor Enhances Surfactant Protein B Expression in Mechanically Ventilated Preterm Pigs

Influence of mesenchymal and biophysical components on distal lung organoid differentiation